Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-18T13:51:18.321Z Has data issue: false hasContentIssue false
  • English
  • Français

Drug safety related to agents used for opioid maintenance therapy

Published online by Cambridge University Press:  23 March 2020

M. Gahr ,
J. Eller ,
C. Hiemke ,
R.W. Freudenmann ,
B.J. Connemann ,
D. Lang  and
C. Schönfeldt-Lecuona
M. Gahr
Affiliation:
University Hospital of Ulm, Psychiatry and Psychotherapy III, Ulm, Germany
J. Eller
Affiliation:
University Hospital of Ulm, Psychiatry and Psychotherapy III, Ulm, Germany
C. Hiemke
Affiliation:
University of Mainz, Psychiatry and Psychotherapy, Mainz, Germany
R.W. Freudenmann
Affiliation:
University Hospital of Ulm, Psychiatry and Psychotherapy III, Ulm, Germany
B.J. Connemann
Affiliation:
University Hospital of Ulm, Psychiatry and Psychotherapy III, Ulm, Germany
D. Lang
Affiliation:
University Hospital of Ulm, Psychosomatic Medicine and Psychotherapy, Ulm, Germany
C. Schönfeldt-Lecuona
Affiliation:
University Hospital of Ulm, Psychiatry and Psychotherapy III, Ulm, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

There is only little data regarding drug safety related to agents used for opioid maintenance therapy (OMT).

Objectives/aims

To study drug safety and the reporting behaviour of adverse drug reactions (ADR) related to OMT.

Methods

A cross-sectional questionnaire-based telephone survey among physicians providing outpatient OMT in a federal state of Germany (n = 176; response rate = 55.7%) was conducted.

Results

Most of the respondents (n = 97/55.1%) reported that they observe ADR related to buprenorphine, [dihydro]codein and [levo]methdone rarely (n = 38/21.6%), very rarely (n = 39/22.2%) or never (n = 20/11.4%). Methadone was reported to be most frequently associated with the occurrence of ADR (n = 82/46.6%), followed by levomethadone (n = 33/18.8%), buprenorphine (n = 6/3.4%), and dihydrocodeine (n = 3/1.7%). Frequently observed ADR related to these agents were gastrointestinal, nervous system and psychiatric disorders, and hyperhidrosis. Methadone and levomethadone (not buprenorphine) were reported to be frequently associated with fatigue, weight gain, and sexual dysfunction. Only buprenorphine was reported to be frequently associated with withdrawal and rebound effects, and drug intolerance. Hundred twenty-nine participants (73.3%) stated that they never report ADR related to OMT, whereas n = 19 (10.8%) did so when referring to ADR related to their complete medical practice (Chi2 = 141.070; df = 1; P < 0.001).

Conclusions

Our data revealed similar patterns of ADR related to outpatient OMT as those reported in the product information or in pain therapy. Motivation to report ADR related to agents used for OMT may be reduced compared to ADR related to the general medical practice.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster viewing: Substance related and addictive disorders
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. s870
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.